A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer
详细信息 查看全文
- 作者：Sjoukje F. Oostinga ; s.oosting@umcg.nl" class="auth_mail" title="E-mail the corresponding author ; Tom W.W. Chenb ; Shao H. Huangc ; Lisa Wangd ; John Waldronc ; Ralph Gilberte ; David Goldsteine ; Gyorgy B. Halmosf ; Max J.H. Witjesg ; Jourik A. Gietemaa ; Brian O&rsquo ; Sullivanc ; Johannes A. Langendijkh ; Lillian L. Siub ; Aaron R. Hansenb
- 关键词：Head and neck squamous cell carcinoma ; Adjuvant ; Postoperative ; Cisplatin ; Radiotherapy ; Involved margins ; Extra-capsular extension
- 刊名：Oral Oncology
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：59
- 期：Complete
- 页码：43-49
- 全文大小：371 K
文摘
- •
Half of high-risk HNSCC patients are not eligible for addition of cisplatin to RT.
- •
Weekly 50 mg/m2 cisplatin results in a higher cumulative dose than 3-weekly 100 mg/m2.
- •
Efficacy of weekly 50 mg/m2 cisplatin remains to be evaluated.